436 related articles for article (PubMed ID: 10634383)
21. Value of postoperative thyroglobulin and ultrasonography for the indication of ablation and ¹³¹I activity in patients with thyroid cancer and low risk of recurrence.
Rosario PW; Xavier AC; Calsolari MR
Thyroid; 2011 Jan; 21(1):49-53. PubMed ID: 20954820
[TBL] [Abstract][Full Text] [Related]
22. [The early detection of metastatic differentiated thyroid cancer using 131I total body scan and treatment with 131I].
Ikekubo K; Hino M; Ito H; Yamaguchi H; Saiki Y; Ui K; Tominaga E; Nakanishi M; Kawai J; Koh T
Kaku Igaku; 1991 Mar; 28(3):247-59. PubMed ID: 1904509
[TBL] [Abstract][Full Text] [Related]
23. Short-term effectiveness of low-dose radioiodune ablative treatment of thyroid remnants after thyroidectomy for differentiated thyroid cancer.
Vermiglio F; Violi MA; Finocchiaro MD; Baldari S; Castagna MG; Moleti M; Mattina F; Pio Lo Presti V; Bonanno N; Trimarchi F
Thyroid; 1999 Apr; 9(4):387-91. PubMed ID: 10319946
[TBL] [Abstract][Full Text] [Related]
24. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer.
Caglar M; Bozkurt FM; Akca CK; Vargol SE; Bayraktar M; Ugur O; Karaağaoğlu E
Nucl Med Commun; 2012 Mar; 33(3):268-74. PubMed ID: 22205241
[TBL] [Abstract][Full Text] [Related]
25. Thyroglobulin and 131I uptake of remaining tissue in patients with differentiated carcinoma after thyroidectomy.
Moser E; Fritsch S; Braun S
Nucl Med Commun; 1988 Apr; 9(4):262-6. PubMed ID: 3399222
[TBL] [Abstract][Full Text] [Related]
26. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal.
Elisei R; Schlumberger M; Driedger A; Reiners C; Kloos RT; Sherman SI; Haugen B; Corone C; Molinaro E; Grasso L; Leboulleux S; Rachinsky I; Luster M; Lassmann M; Busaidy NL; Wahl RL; Pacini F; Cho SY; Magner J; Pinchera A; Ladenson PW
J Clin Endocrinol Metab; 2009 Nov; 94(11):4171-9. PubMed ID: 19850694
[TBL] [Abstract][Full Text] [Related]
27. Value of thyroglobulin to 131I uptake ratio in selection of initial therapy dose of 131I in patients with differentiated thyroid carcinoma.
Zerva B; Koutsikos J; Palestidis C; Kounadi E; Gerali S
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):348-54. PubMed ID: 17043633
[TBL] [Abstract][Full Text] [Related]
28. Combination of radioiodine (131I) and probe-guided surgery for persistent or recurrent thyroid carcinoma.
Travagli JP; Cailleux AF; Ricard M; Baudin E; Caillou B; Parmentier C; Schlumberger M
J Clin Endocrinol Metab; 1998 Aug; 83(8):2675-80. PubMed ID: 9709930
[TBL] [Abstract][Full Text] [Related]
29. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer.
Ozata M; Suzuki S; Miyamoto T; Liu RT; Fierro-Renoy F; DeGroot LJ
J Clin Endocrinol Metab; 1994 Jul; 79(1):98-105. PubMed ID: 8027262
[TBL] [Abstract][Full Text] [Related]
30. Quantitative reverse transcription-polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinoma.
Ringel MD; Balducci-Silano PL; Anderson JS; Spencer CA; Silverman J; Sparling YH; Francis GL; Burman KD; Wartofsky L; Ladenson PW; Levine MA; Tuttle RM
J Clin Endocrinol Metab; 1999 Nov; 84(11):4037-42. PubMed ID: 10566646
[TBL] [Abstract][Full Text] [Related]
31. Success rate of thyroid remnant ablation for differentiated thyroid cancer based on 5550 MBq post-therapy scan.
Hommel I; Pieters GF; Rijnders AJ; van Borren MM; de Boer H
Neth J Med; 2016 May; 74(4):152-7. PubMed ID: 27185773
[TBL] [Abstract][Full Text] [Related]
32. Predictive value of thyroglobulin changes for the efficacy of thyroid remnant ablation.
Savelli G; Chiti A; Rodari M; Schreiner F; Maccauro M; Aliberti G; Gerali A; Bombardieri E
Tumori; 2001; 87(1):42-6. PubMed ID: 11669557
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of thyroglobulin after thyroidectomy before ablative radioiodine therapy in thyroid cancer.
Grünwald F; Menzel C; Fimmers R; Zamora PO; Biersack HJ
J Nucl Med; 1996 Dec; 37(12):1962-4. PubMed ID: 8970514
[TBL] [Abstract][Full Text] [Related]
34. [Compared to whole body scanning thyroglobulin assay is reliable in the follow-up of thyroidectomized patients with thyroid carcinoma].
van den Bergh JP; Pieters GF; Beex LV; Ross HA; Corstens FH; Smals AG
Ned Tijdschr Geneeskd; 1993 Jul; 137(27):1344-8. PubMed ID: 8350939
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment.
Pacini F; Capezzone M; Elisei R; Ceccarelli C; Taddei D; Pinchera A
J Clin Endocrinol Metab; 2002 Apr; 87(4):1499-501. PubMed ID: 11932271
[TBL] [Abstract][Full Text] [Related]
36. Follow-up regimen of differentiated thyroid carcinoma in thyroidectomized patients after thyroid hormone withdrawal.
Oyen WJ; Verhagen C; Saris E; van den Broek WJ; Pieters GF; Corsten FH
J Nucl Med; 2000 Apr; 41(4):643-6. PubMed ID: 10768565
[TBL] [Abstract][Full Text] [Related]
37. The effect of posttherapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer.
Grewal RK; Tuttle RM; Fox J; Borkar S; Chou JF; Gonen M; Strauss HW; Larson SM; Schöder H
J Nucl Med; 2010 Sep; 51(9):1361-7. PubMed ID: 20720058
[TBL] [Abstract][Full Text] [Related]
38. Clinical significance of hepatic visualization on iodine-131 whole-body scan in patients with thyroid carcinoma.
Chung JK; Lee YJ; Jeong JM; Lee DS; Lee MC; Cho BY; Koh CS
J Nucl Med; 1997 Aug; 38(8):1191-5. PubMed ID: 9255147
[TBL] [Abstract][Full Text] [Related]
39. Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment.
Pace L; Klain M; Albanese C; Salvatore B; Storto G; Soricelli A; Salvatore M
Eur J Nucl Med Mol Imaging; 2006 Feb; 33(2):179-83. PubMed ID: 16205897
[TBL] [Abstract][Full Text] [Related]
40. Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma.
Lubin E; Mechlis-Frish S; Zatz S; Shimoni A; Segal K; Avraham A; Levy R; Feinmesser R
J Nucl Med; 1994 Feb; 35(2):257-62. PubMed ID: 8294995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
